SRT 2183 did not affect AMPKα phosphorylation in sirt1 -/--derived osteoclasts compared with vehicle-treated osteoclasts in the RANKL co-administration design. SRT 2183 inhibited proliferation in Reh and Nalm-6 cells. In LN229 cells, SRT 2183 significantly decreased the capability to grow clonally. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
AMPKα phosphorylation in sirt1 -/--derived osteoclasts
Cell-based study · sirt1 -/--derived osteoclasts [1]
In sirt1 -/--derived osteoclasts, SRT 2183 was co-administered with RANKL at 1μM. AMPKα phosphorylation was unaffected compared with vehicle-treated osteoclasts.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1μM
- Exposure duration
- 4 days post RANKL stimulation
- Method
- co-administrated with RANKL
- Vehicle
- 0.01% DMSO
- Co-treatment
- Other interventions in this design: M-CSF 10%; RANKL 10 ng/ml. Compound effect isolated by the comparison: SRT2183- and vehicle-treated osteoclasts.
Methods and source locations
Compound reported in the paper: SRT 2183
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > In vitro assays of osteoclast differentiation (S10); Methods > Compounds (S14, S15, S18); Results > SRT2183 inhibits osteoclastogenesis in sirt1-/--derived bone marrow macrophages (S72); Fig 4 legend (S131, S132)
AMPKα phosphorylation (Thr172): AMPKα phosphorylation (Thr172); comparator: vehicle-treated osteoclasts — Results > SRT2183 inhibits osteoclastogenesis in sirt1-/--derived bone marrow macrophages (S72); Fig 4 legend (S131)
Proliferation inhibition in Reh cells
Cell-based study · Reh cells [2]
In Reh cells, SRT 2183 treatment inhibited proliferation, with an IC50 of approximately 8.7 μℳ at 48 h.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h
- Vehicle
- dimethyl sulfoxide (DMSO)
- Reported limits
- Not stated in the sentences used: dose, route, control.
Methods and source locations
Compound reported in the paper: SRT 2183
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results (S4, S6); Materials and Methods > Drugs (S69); Figure 1 legend (S122)
inhibition of proliferation: inhibition of proliferation — Results (S6)
Clonal growth in LN229 cells
Cell-based study · LN229 [3]
LN229 cells were treated with SRT 2183 at 10 μM. Treatment significantly decreased their capability to grow clonally after a 2-week treatment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 uM
- Exposure duration
- 2-week treatment
- Method
- incubated with 10 μM SRT2183
- Vehicle
- dimethyl sulfoxide (DMSO)
Methods and source locations
Compound reported in the paper: SRT 2183
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Cells, reagents, and plasmid (S7); Methods > Clonogenic assays (S18); Results > SRT2183 suppresses glioma cell growth (S59, S62)
number of colonies in a clonogenic assay: number of colonies in a clonogenic assay; comparator: vehicle control — Results > SRT2183 suppresses glioma cell growth (S59, S62)
Proliferation inhibition in Nalm-6 cells
Cell-based study · Nalm-6 cells [2]
In Nalm-6 cells, treatment inhibited proliferation, with a reported value of approximately 3.2 μℳ at 48 h.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h
- Vehicle
- dimethyl sulfoxide (DMSO)
- Reported limits
- Not stated in the sentences used: dose, route, control.
Methods and source locations
Compound reported in the paper: SRT 2183
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results (S4, S6); Materials and Methods > Drugs (S69); Figure 1 legend (S122)
inhibition of proliferation: inhibition of proliferation — Results (S6)